hi All,
Got to admit it all looks a bit touch and go now. Selling a revenue stream to kick the can down the road makes sense if you can replace that revenue stream.
But the question is how are we looking moving forward. To me, if that Testosterone generic has floundered then I think the company is in a dead man walking situation.
Perhaps if there is the beginnings of a new revenue stream building then another CR may be possible once the money from the Lenzetto sale is gone.
Bankruptcy seems the likely option to me. It’s going to be an interesting quarterly.
Ann: Gedeon Richter buyout Lenzetto Royalties for EUR4.1million, page-9
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.3¢ |
Change
0.001(1.61%) |
Mkt cap ! $18.31M | |||
| Open | High | Low | Value | Volume |
| 6.3¢ | 6.3¢ | 6.3¢ | $774 | 12.28K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3584 | 6.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.9¢ | 48386 | 2 |
View Market Depth
| Last trade - 13.11pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.7¢ |
Change
0.001 ( 8.06 %) |
||||
| Open | High | Low | Volume | ||
| 6.7¢ | 6.7¢ | 6.7¢ | 16000 | ||
| Last updated 10.26am 17/05/2024 ? | |||||
| ACR (ASX) Chart |